Image alt tag

Error!

There was a problem contacting the server. Please try after sometime.

Sorry, we are unable to process your request.

Error!

We're sorry, but the Insights and Intelligence Tool is temporarily unavailable

If this problem persists, or if you need immediate assistance, please contact Customer Service at 1-888-522-2388.

Error!

We're sorry, but the Literature Center checkout function is temporarily unavailable.

If this problem persists, or if you need immediate assistance, please contact Customer Service at 1-888-522-2388.

Tracked Funds

You have 0 funds on your mutual fund watch list.

Begin by selecting funds to create a personalized watch list.

(as of 12/05/2015)

Pending Orders

You have 0 items in your cart.

Subscribe and order forms, fact sheets, presentations, and other documents that can help advisers grow their business.

Reset Your Password

Financial Professionals*

Your password must be a minimum of characters.

Confirmation Message

Your LordAbbett.com password was successully updated. This page will be refreshed after 3 seconds.

OK

 

Calibrated Dividend Growth Fund

Summary

Summary

What is the Calibrated Dividend Growth Fund?

The Fund seeks to deliver total return by investing primarily in stocks of large U.S. companies that have a history of increasing their dividends.

HIGH-QUALITY UNIVERSE

Companies with consistent dividend growth are often market leaders with stable business models, strong balance sheets, and management teams committed to shareholders.

LOWER RISK PROFILE

Focusing on U.S. companies that have consistently grown their dividends often provides investors with an equity portfolio that has a lower risk profile than the broader market.

GROWTH AND RISING INCOME

A portfolio of consistent dividend growers may provide investors with long-term growth and rising income. Many of these companies have grown their dividends much faster than inflation.

Fund Basicsas of 10/31/2019

Total Net Assets
$2.49 B
Inception Date
04/05/2017
Dividend Frequency
Quarterly
Fund Expense Ratio
0.62%
Number of Holdings
80

Yield

12-Month Dividend Yield 1 as of 12/06/2019  

w/o sales charge 1.63%

30-Day Standardized Yield 2 as of 10/31/2019  

1.76%

Fund Expense Ratio :

0.62%

YTD 1-YR 3-YR 5-YR 10-YR Since Inception
w/o sales charge 23.86% 13.90% 12.79% 9.93% 11.97% -
Lipper Category Avg. Equity Income Funds 21.13% 10.77% 9.87% 7.40% 10.71% -
S&P 500 Index 27.63% 16.11% 14.88% 10.98% 13.44% -

Fund Expense Ratio :

0.62%

Fund Expense Ratio :

0.62%

YTD 1-YR 3-YR 5-YR 10-YR Since Inception
w/o sales charge 21.70% 8.71% 12.66% 10.91% 12.08% -
Lipper Category Avg. Equity Income Funds 16.98% 3.64% 9.46% 7.58% 10.71% -
S&P 500 Index 20.55% 4.25% 13.39% 10.84% 13.24% -

Fund Expense Ratio :

0.62%

RELATED CONTENT

Dividend-Growth Stocks: An Alternative to Market Timing
February 4, 2019

Instead of jumping in and out of stocks, investors may be better served by understanding the types of equities that historically have performed relatively well during bouts of market volatility.

How Dividend Growers Could Provide a Smoother Ride
November 12, 2018

A portfolio of stocks with steadily increasing dividends offers the opportunity for rising income over time with less volatility than the broader market.

Holdings as of 10/31/2019View Portfolio

Holding Assets
Microsoft Corp. 3.1%
Procter & Gamble Co. 2.8%
Abbott Laboratories 2.8%
Chevron Corp. 2.5%
Union Pacific Corp. 2.4%
Comcast Corp. 2.3%
Verizon Communications, Inc. 2.3%
AT&T, Inc. 2.3%
Wal-Mart Stores, Inc. 2.2%
Medtronic, Inc. 2.1%
% of Total Assets 24.8%

INVESTMENT TEAM

Walter H. Prahl
Walter H. Prahl, Ph.D.

Partner & Director

34 Years of Industry Experience

Marc O. Pavese
Marc O. Pavese, Ph.D.

Partner & Portfolio Manager

19 Years of Industry Experience

David J. Linsen
David J. Linsen, CFA

Partner & Director of U.S. Equities

23 Years of Industry Experience

Darnell Azeez
Darnell Azeez, CFA

Portfolio Manager

17 Years of Industry Experience

Servesh Tiwari
Servesh Tiwari, CFA

Portfolio Manager

16 Years of Industry Experience

Supported By 37 Investment Professionals with 18 Years Avg. Industry Experience

Your Representative

To contact your representative, enter your zip code and select your channel below.

Performance

Performance

12-Month Dividend Yield 1 as of 12/06/2019  

w/o sales charge 1.63%

30-Day Standardized Yield 2 as of 10/31/2019  

  Subsidized5 Un-Subsidized6
w/o sales charge 1.76% 1.76%

Fund Expense Ratio :

0.62%

YTD 1-YR 3-YR 5-YR 10-YR Since Inception
w/o sales charge 23.86% 13.90% 12.79% 9.93% 11.97% -
Lipper Category Avg. Equity Income Funds 21.13% 10.77% 9.87% 7.40% 10.71% -
S&P 500 Index 27.63% 16.11% 14.88% 10.98% 13.44% -

Fund Expense Ratio :

0.62%

Fund Expense Ratio :

0.62%

YTD 1-YR 3-YR 5-YR 10-YR Since Inception
w/o sales charge 21.70% 8.71% 12.66% 10.91% 12.08% -
Lipper Category Avg. Equity Income Funds 16.98% 3.64% 9.46% 7.58% 10.71% -
S&P 500 Index 20.55% 4.25% 13.39% 10.84% 13.24% -

Fund Expense Ratio :

0.62%

Year Fund Returns S&P 500 Index
2018 -4.43% -4.38%
2017 19.49% 21.83%
2016 15.62% 11.96%
2015 -2.05% 1.38%
2014 11.95% 13.69%
2013 28.39% 32.39%
2012 13.47% 16.00%
2011 0.32% 2.11%
2010 15.25% 15.06%
2009 23.89% 26.46%
2008 -26.98% -
2007 3.48% -
2006 - -
Year Q1 Q2 Q3 Q4 Yearly Returns
2019 11.99% 4.10% 4.39% - 24.46%
2018 -2.71% 1.43% 8.43% -10.68% -4.43%
2017 4.47% 2.57% 3.48% 7.77% 19.49%
2016 6.16% 4.99% 0.82% 2.89% 15.62%
2015 -0.03% -2.17% -5.63% 6.12% -2.05%
2014 1.59% 4.82% -1.39% 6.61% 11.95%
2013 10.51% 1.43% 5.37% 8.71% 28.39%
2012 10.87% -3.61% 5.77% 0.39% 13.47%
2011 5.69% -0.11% -13.83% 10.26% 0.32%
2010 4.87% -8.09% 10.38% 8.32% 15.25%
2009 -5.04% 9.96% 12.53% 5.44% 23.89%
2008 -8.51% -0.30% -8.99% -12.03% -26.98%
2007 3.57% 4.34% -1.07% -3.21% 3.48%
2006 - - - 8.01% -

NAV HISTORICAL PRICES

Date Net Asset Value

Portfolio

Portfolio

Portfolio Positioning as of 09/30/2019

  • Abbott Laboratories, a health care products manufacturer, is the portfolio’s largest overweight position relative to the portfolio’s benchmark, the S&P 500 Index, as of September 30, 2019. We believe the firm has demonstrated strong management execution, robust revenue growth, and that there is an opportunity to expand margins. The company has a robust pipeline in the medical device and diagnostic segments, which we believe will allow the company to maintain high revenue growth rates relative to its peers.
  • Medtronic, Inc., a device based medical therapy distributor, is another of the portfolio’s overweight positions relative to its benchmark. We believe the firm has a promising pipeline of medical devices and has consistently exhibited stable earnings, which makes the security an attractive long term prospect.
  • The portfolio also is overweight in Union Pacific Corp., a rail transportation company, relative to the benchmark. We believe that Union Pacific is attractive because of the expected implementation of the Precision Scheduled Railroading model, which is likely to result in further productivity gains.

PORTFOLIO DETAILS as of 10/31/2019

Total Net Assets
$2.49 B
Number of Holdings
80
Weighted Average Market Cap.
147.5 B
P/B Ratio
3.9x
Portfolio Turnover Ratio as of 11/30/2018
50.6%
P/E Ratio
21.8x

Contributors & Detractors as of  09/30/2019

Contributors

Holding Contribution
Target Corp. 0.3%
Procter & Gamble Co. 0.3%
Medtronic, Inc. 0.3%
AT&T, Inc. 0.3%
Sherwin-Williams Co. 0.3%

Detractors

Holding Contribution
Xilinx, Inc. -0.2%
Johnson & Johnson, Inc. -0.1%
Chevron Corp. -0.1%
Union Pacific Corp. -0.1%
CSX Corp. -0.1%

Attribution Analysis 

Calibrated Dividend Growth Fund Benchmark Variance
Sector Avg. Weight Base Return Avg. Weight Base Return Stock Selection Group Weight Total

Dividends & Cap Gains

Dividends & Cap Gains

Dividend Payments

For
YTD Dividends Paidas of 12/06/2019
$0.211
Dividend Frequency
Quarterly
Record Date Ex-Dividend Date Reinvest & Payable Date Dividend Reinvest Price
09/26/2019 09/27/2019 09/27/2019 $0.06920 $16.24
06/27/2019 06/28/2019 06/28/2019 $0.07170 $15.71
03/28/2019 03/29/2019 03/29/2019 $0.07080 $15.16

Upcoming Dividend Payment Dates

This section lists all anticipated income and Capital Gain distribution dates and any actual distributions are subject to adequacy of earnings and must be approved by the Board of Directors/Trustees. Please note that dates are subject to change.

Record Date Ex-Dividend Date Reinvest & Payable Date
12/26/2019 12/27/2019 12/27/2019

Capital Gains Distributions

For
Record Date Reinvest & Payable Date Long-term Short-term * Total Reinvest Price
12/17/2018 12/18/2018 $0.7838 $0.2422 $1.0260 $13.80

Upcoming Capital Gain Distribution

This section lists all anticipated income and Capital Gain distribution dates and any actual distributions are subject to adequacy of earnings and must be approved by the Board of Directors/Trustees. Please note that dates are subject to change.

Record Date Ex-Dividend Date
12/17/2019 12/18/2019

Fees & Expenses

Fees & Expenses

EXPENSE RATIOas of 11/30/2019

0.62%

Fund Documents

Fund Documents

Download fund documents & literature, create email subscriptions, and place direct mail order

0Documents selected
Order
Summary Prospectus
Publish Date:11/03/2015
n/a
Statutory Prospectus
Publish Date:11/03/2015
n/a
Prospectus (XBRL)
Publish Date:11/03/2015
SAI
Publish Date:11/03/2015
Annual Report
Publish Date:11/03/2015
Semi-Annual Report
Publish Date:11/03/2015
Fact Sheet
Publish Date:11/03/2015
Commentary
Publish Date:11/03/2015
Flyer
Publish Date:11/03/2015
Publish Date:11/03/2015

To order literature visit full website

You may add to your cart by selecting quantities in each row below.

No rows selected. Please Go back and select at least one fund document

 
Quantity
Quantity
Remove
Remove

Class F3 - The inception date for Class F3 shares is April 4, 2017. The performance quotations for Class F3 are based on the following methods of calculation: (a) for periods prior to June 30, 2015,  a figure is used based on the historical performance of the Fund’s Class I Shares, since inception, restated to reflect all charges and fees applicable to Class F3 shares; (b) for periods prior to April 4, 2017 but after June 30, 2015, performance is based on the historical performance of the Fund’s Class R6 shares, which have an equivalent expense ratio to the Fund’s F3 shares; and (c) for periods after April 4, 2017, actual Class F3 performance is used, which reflects all charges and fees applicable to Class F3 shares.

Class F3 shares are only offered to certain eligible investors. For additional information, see the Fund’s current prospectus.

The S&P 500® Index is widely regarded as the standard for measuring large cap U.S. stock market performance and includes a representative sample of leading companies in leading industries.

Select funds to run a Morningstar Hypothetical Report.

    Please confirm your literature shipping address

    Please review the address information below and make any necessary changes.

    All literature orders will be shipped to the address that you enter below. This information can be edited at any time.

    Current Literature Shipping Address

    * Required field